Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate

Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody–Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study

(2017) Kathleen N. Moore et al.   JOURNAL OF CLINICAL ONCOLOGY

Development of a New Folate-Derived Ga-68-Based PET Imaging Agent

(2017) Christian Brand et al.   MOLECULAR IMAGING AND BIOLOGY

Strategies and challenges for the next generation of antibody–drug conjugates

(2017) Alain Beck et al.   NATURE REVIEWS DRUG DISCOVERY

A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse

(2016) Ignace Vergote et al.   JOURNAL OF CLINICAL ONCOLOGY

Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites

(2016) Samira M. Sadowski et al.   JOURNAL OF CLINICAL ONCOLOGY

Development of Companion Diagnostics

(2016) David A. Mankoff et al.   SEMINARS IN NUCLEAR MEDICINE

Nanoreporter PET predicts the efficacy of anti-cancer nanotherapy

(2016) Carlos Pérez-Medina et al.   Nature Communications

Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments

(2015) J. A. Ledermann et al.   ANNALS OF ONCOLOGY

Companion Diagnostics and Molecular Imaging

(2015) Ameya D. Puranik et al.   CANCER JOURNAL

IMGN853, a Folate Receptor-  (FR )-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FR -Expressing Tumors

(2015) O. Ab et al.   MOLECULAR CANCER THERAPEUTICS

Companion diagnostics and molecular imaging-enhanced approaches for oncology clinical trials

(2015) Ronald Van Heertum et al.   Drug Design Development and Therapy

Phase II study of treatment of advanced ovarian cancer with folate-receptor-targeted therapeutic (vintafolide) and companion SPECT-based imaging agent (99mTc-etarfolatide)

(2014) R. T. Morris et al.   ANNALS OF ONCOLOGY

The folate receptor as a rational therapeutic target for personalized cancer treatment

(2014) Yehuda G. Assaraf et al.   DRUG RESISTANCE UPDATES

Companion Diagnostics for Targeted Cancer Drugs – Clinical and Regulatory Aspects

(2014) Dana Olsen et al.   Frontiers in Oncology

Applying PET to Broaden the Diagnostic Utility of the Clinically Validated CA19.9 Serum Biomarker for Oncology

(2013) N. T. Viola-Villegas et al.   JOURNAL OF NUCLEAR MEDICINE

89Zr-DFO-J591 for ImmunoPET of Prostate-Specific Membrane Antigen Expression In Vivo

(2010) J. P. Holland et al.   JOURNAL OF NUCLEAR MEDICINE

Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine

(2010) Maria J W D Vosjan et al.   Nature Protocols